December 9, 2015
Bristol-Myers wraps up Cardioxyl buy. Dividend increase
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Bristol-Myers Squibb
October 29, 2015
FDA approved BMS’s Yervoy
U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
October 15, 2015
BMS – Five Prime Agreement
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. have announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications.
October 5, 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo + Yervoy Regimen
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.